Close Menu

NEW YORK – Japan-based pharmaceutical company Takeda today announced that the European Commission has approved its selective tyrosine kinase inhibitor brigatinib (Alunbrig) as a monotherapy for patients with ALK-positive, advanced non-small cell lung cancer as a first-line option.

The approval presents another treatment option for patients with ALK rearrangements, who make up three-to-five percent of all patients with metastatic NSCLC.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.